See how cancer researchers around the world use Illumina technology

Featured Cancer Researchers

Find out what cancer researchers are discovering with Illumina technology.

Graham Taylor, Ph.D. FRCPath
Translational Genomics Unit, Leeds University
President of the Human Genome Variation Society

Regarding cancer patient genome sequencing translational research: “MiSeq allows the speed of data generation that fits into a clinical treatment context.”

Access PDF
Image
Steve McPhail
President and Chief Executive Officer, Expression Analysis

Regarding a study to inform clients about the benefits of RNA-Seq for transcriptome analysis of breast cancer cells: “We felt the data would be persuasive in showing how mRNA-Seq could provide additional information about the biology of what they were studying.”

Access PDF
Image
Seishi Ogawa, Ph.D.
University of Tokyo

“Cancer is caused by genetic mutations. To fully understand their functional consequences, it is essential to view the complete spectrum of genetic alterations both at the DNA and RNA level, as well as copy number and methylation changes. Our research aims to understand the genetic basis of various human cancers using revolutionized sequencing technologies.”

Read Paper
Image
Susanne Horn, Ph.D.
Postdoctoral Researcher
Division of Molecular Genetic Epidemiology
German Cancer Research Center

“Following targeted enrichment, we used the HiSeq 2000 to perform next-generation sequencing of familial melanoma samples, identifying a promoter mutation of the TERT gene. We then identified similar mutations in somatic melanoma, providing a novel genetic insight into key mutations in melanoma.”

Read Paper
Image
Yasser Riazalhosseini, Ph.D.
Assistant Professor, Department of Human Genetics, McGill University
Principal Investigator, McGill University and Genome Quebec Innovation Center

“With the Nextera Rapid Capture Exome Kit, we generate libraries using low DNA amounts that result in high-quality sequencing. We are conducting studies on less-studied cancers to understand the underlying genetic aberrations.”

Access PDF
Image
Trilochan Sahoo, MD
Director of Cytogenetics, CombiMatrix

“Now that we have whole-genome tools such as microarrays and NGS, we can analyze the entire genome from a few malignant cells at a resolution that allows us to identify abnormalities and look for rearrangements with a very high degree of precision.”

Access PDF
Image
Dr. Nicholas Navin
Assistant Professor in the Department of Genetics,
University of Texas MD Anderson Cancer Center

“Tools like the Nextera Rapid Capture Exome kit are allowing researchers to get a whole new view of tumors and their genetic diversity and complexity.”

Access PDF
Image
Interested in receiving newsletters, case studies, and information on cancer genomics? Enter your email address.